American Journal of Ophthalmology
Volume 136, Issue 1 , Pages 47-54 , July 2003

Mortality after deferral of treatment or no treatment for choroidal melanoma

  • Bradley R Straatsma, MD

      Affiliations

    • Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at University of California Los Angeles (B.R.S., R.C., R.E.E.), Los Angeles, California, USA
    • Corresponding Author InformationInquiries to Bradley R. Straatsma, MD, Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, 100 Stein Plaza, UCLA, Los Angeles, CA, USA 90095-7000; fax: (310) 206-4293.
    • ,
  • Marie Diener-West, PhD

      Affiliations

    • Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University (M.D.-W.), Baltimore, Maryland, USA
    • ,
  • Robert Caldwell, PA

      Affiliations

    • Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at University of California Los Angeles (B.R.S., R.C., R.E.E.), Los Angeles, California, USA
    • ,
  • Robert E Engstrom Jr, MD

      Affiliations

    • Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at University of California Los Angeles (B.R.S., R.C., R.E.E.), Los Angeles, California, USA
    • ,
  • For The Collaborative Ocular Melanoma Study Group

      Affiliations

    • A complete listing of the Collaborative Ocular Melanoma Study (COMS) group is available in The American Journal of Ophthalmology 1998;125:757–765.

,Accepted 23 December 2002.

References 

  1. Fuchs E. Das Sarkom des Uvealtractus. Wien: Wilhelm Braumüller, 1882. After Reese AB. Tumors of the eye. New York: Harper and Row; 1963;
  2. Weve H. On diathermy in ophthalmic practice. Trans Ophthalmol Soc U K. 1939;59:43–80
  3. Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol. 1966;50:147–155
  4. Lommatzsch PK. Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators. Surv Ophthalmol. 1974;19:85–100
  5. Davidorf FH, Makley TA, Lang JR. Radiotherapy of malignant melanoma of the choroid. Trans Am Acad Ophthalmol Otolaryngol. 1976;81:849–861
  6. Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine-125. Ophthalmology. 1980;87:582–590
  7. Gragoudas ES, Goitein M, Verhey L, et al.  Proton beam irradiation of uveal melanoma (results of a 5 1/2 year study). Arch Ophthalmol. 1982;100:928–934
  8. Char DH, Saunders W, Castro JR, et al.  Helium ion therapy for choroidal melanoma. Ophthalmology. 1983;90:1219–1225
  9. Shields JA, Augsburger JJ, Brady LW, Day JL. Cobalt plaque therapy of posterior uveal melanoma. Ophthalmology. 1982;89:1201–1207
  10. Meyer-Schwickerath G. The preservation of vision by treatment of intraocular tumors with light coagulation. Arch Ophthalmol. 1961;66:36–44
  11. Boniuk M, Girard LJ. Malignant melanoma of the choroid treated with photocoagulation, transscleral diathermy and implanted radon seeds. Am J Ophthalmol. 1965;59:212–216
  12. Foulds WS, Damato BE. Alternatives to enucleation in the management of choroidal melanoma. Aust NZ J Ophthalmol. 1986;14:19–27
  13. Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases. Ophthalmology. 2002;109:2; 225–234
  14. Saraux H, Belosse B. Histoire naturelle des mélanomes malins de la choroïde. J Fr Ophtalmol. 1988;11:169–175
  15. Augsburger JJ, Vrabec TR. Impact of delayed treatment in growing posterior uveal melanomas. Arch Ophthalmol. 1993;111:1382–1386
  16. Collaborative Ocular Melanoma Study Group . Design and methods of a clinical trial for a rare condition (the Collaborative Ocular Melanoma Study. COMS report no. 3). Control Clin Trials. 1993;14:362–391
  17. Collaborative Ocular Melanoma Study Group . COMS manual of procedures, PB95–179693. Springfield, VA: National Technical Information Service; 1995;
  18. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West M, McLaughlin JA  for the Collaborative Ocular Melanoma Study Research Group . Enucleation versus plaque irradiation for choroidal melanoma. Ophthalmology. 1988;95:1000–1004
  19. Collaborative Ocular Melanoma Study Group . The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, I (characteristics of patients enrolled and not enrolled. COMS report no. 9). Am J Ophthalmol. 1998;125:767–778
  20. Collaborative Ocular Melanoma Study Group . The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, II (initial mortality findings. COMS report no. 10). Am J Ophthalmol. 1998;125:779–796
  21. Collaborative Ocular Melanoma Study Group . The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, III (local complications and observations following enucleation: COMS report no. 11). Am J Ophthalmol. 1998;126:362–372
  22. Collaborative Ocular Melanoma Study Group . The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II (characteristics of patients enrolled and not enrolled. COMS report no. 17). Arch Ophthalmol. 2001;119:951–965
  23. Collaborative Ocular Melanoma Study Group . The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III (initial mortality findings. COMS report no. 18). Arch Ophthalmol. 2001;119:969–982
  24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  25. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187–202
  26. Collaborative Ocular Melanoma Study Group . Histopathologic characteristics of uveal melanoma in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998;125:745–766
  27. Laquis SJ, Freeman JM, Fleming JC, Wilson MW, Haik BG. A rapid growing choroidal melanoma. Am J Ophthalmol. 2002;133:580
  28. Friberg TR, Fineberg E, McQuaig S. Extremely rapid growth of a primary choroidal melanoma. Arch Ophthalmol. 1983;101:1375–1377
  29. Manschot WA. The natural history of uveal melanomas and its therapeutic consequences. Doc Ophthalmol. 1980;50:83–99
  30. Manschot WA, Lee WR, van Strik R. Uveal melanoma: updated considerations on current management modalities. Int Ophthalmol 1995–96;19:203–209
  31. Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumor doubling time in metastatic malignant melanoma of the uvea. Ophthalmology. 2000;107:1443–1449
  32. Rennie I. Melanomas, metastases, and survival. [Editorial] Br J Ophthalmol. 1993;77:685–687
  33. Sisley K, Rennie IG, Cottam DW, Potter AM, Potter CW, Rees RC. Cytogenetic findings in six posterior uveal melanomas. Genes Chrom Cancer. 1990;2:205–209
  34. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst. 1990;82:1765–1769
  35. Sisley K, Cottam DC, Rennie IG, et al.  Non-random abnormalities of chromosomes 3, 6 and 8 associated with posterior uveal melanoma. Genes Chrom Cancer. 1992;5:197–200
  36. Cottam DW, Rennie IG, Woods K, Parsons MA, Bunning RAD, Rees RC. Gelatinolytic metalloproteinase secretion patterns in ocular melanoma. Ophthalmol Vis Sci. 1992;33:1923–1927
  37. Frost PH, Butterfield LH, Dissette VB, Economou JS, Bonavida B. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. J Immunol. 2001;166:3564–3573
  38. Ribas A, Butterfield LH, Hu B, et al.  Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res. 2000;60:2218–2224

☆ This study was supported by the National Eye Institute and the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Research to Prevent Blindness, New York, New York.

PII: S0002-9394(02)02270-5

doi: 10.1016/S0002-9394(02)02270-5

American Journal of Ophthalmology
Volume 136, Issue 1 , Pages 47-54 , July 2003

Article Tools

* Image Usage & Resolution